MARKET

XERS

XERS

Xeris Biopharma Holdings
NASDAQ
5.46
-0.02
-0.37%
Closed 18:23 03/13 EDT
OPEN
5.47
PREV CLOSE
5.48
HIGH
5.62
LOW
5.41
VOLUME
1.47M
TURNOVER
0
52 WEEK HIGH
10.08
52 WEEK LOW
3.805
MARKET CAP
941.47M
P/E (TTM)
1706.25
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at XERS last week (0309-0313)?
Weekly Report · 2h ago
Weekly Report: what happened at XERS last week (0302-0306)?
Weekly Report · 03/09 09:29
Assessing Xeris Biopharma Holdings (XERS) Valuation After Profitability Milestone And 2026 Revenue Guidance
Simply Wall St · 03/09 03:17
Xeris Pharmaceuticals Earnings Call Highlights Rapid Growth
TipRanks · 03/09 00:21
Xeris Biopharma Chief Legal Officer and Corporate Secretary Beth Hecht Disposes of Common Shares
Reuters · 03/04 22:29
Xeris Biopharma: Undervalued Given The Potential Of Its Drug Portfolio
Seeking Alpha · 03/04 12:29
Analysts Offer Insights on Healthcare Companies: Prime Medicine, Inc. (PRME) and Xeris Pharmaceuticals (XERS)
TipRanks · 03/03 15:50
Xeris Biopharma (XERS) Turns Trailing Profitability Into Test Of Bullish Growth Narrative
Simply Wall St · 03/03 00:37
More
About XERS
Xeris Biopharma Holdings, Inc. is a biopharmaceutical company focused on improving patient lives by developing and commercializing products across a range of therapies. It has three commercially available products: Recorlev, Gvoke, and Keveyis. Recorlev is for the treatment of endogenous Cushing’s syndrome. Gvoke is a ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is a therapy for primary periodic paralysis. It also has a pipeline of development programs led by XP-8121, a phase III-ready, once-weekly subcutaneous injection for hypothyroidism. It is pursuing formulation and development partnerships to apply its XeriSol and XeriJect formulation technologies to enhance the drug delivery and clinical profile of other companies’ proprietary drugs and biologics. Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adults with Cushing's syndrome for whom surgery is not an option or has not been curative.

Webull offers Xeris Biopharma Holdings Inc stock information, including NASDAQ: XERS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, XERS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading XERS stock methods without spending real money on the virtual paper trading platform.